Rethinking cardiovascular prevention: cost-effective cholesterol lowering for statin-intolerant patients in Australia and the UK
Authors' conclusion
Ezetimibe and bempedoic acid, both alone and in combination, are cost-effective for long-term primary prevention of CVD in a range of people with statin intolerance, depending on their baseline risk of CVD.
Study context
- Population
- Simulated statin-intolerant individuals, primary prevention of cardiovascular disease (CVD), aged 40 to 85 years, Australia and UK
- Participants
- 108 simulated individuals
- Comparison
- Non-statin lipid-lowering therapy initiated at age 40 years vs no intervention until a CV event
- Outcome
- Incremental cost-effectiveness ratio vs thresholds of 28 000 AUD (Australia) and 25 000 GBP (UK) per quality adjusted life year gained
Methodological detailsmicrosimulation model, Australian and UK national healthcare system perspective
- Microsimulation model
- Australian and UK national healthcare system perspective
Main finding
As reported in the abstract
Proportion of individuals in whom therapy was cost-effective, Australia (current prices)
Further findings
| Outcome | Values |
|---|---|
| Proportion of individuals in whom therapy was cost-effective, UK | Ezetimibe 90.7% · Bempedoic acid 4.6% · Bempedoic acid + ezetimibe 10.2% · Inclisiran 0.0% · Evolocumab 0.0% |
- Proportion of individuals in whom therapy was cost-effective, UK: discounted 3.5% annually (UK)
Bempedoic acid cost-effectiveness by LDL-C and SBP
- Predominantly among LDL-C ≥4.0 mmol/L and SBP ≥140 mmHg (Australia)
- Predominantly among LDL-C ≥5.0 mmol/L and SBP ≥160 mmHg (UK)
Original publication
Rethinking cardiovascular prevention: cost-effective cholesterol lowering for statin-intolerant patients in Australia and the UK. Eur J Prev Cardiol. Published 21 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →